Nimes Cedex 9

• Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction Recruiting
  2023-508798-94-00 5 2025-02-11 Heart failure
• Combination of baricitinib and anti-TNF in rheumatoid arthritis Recruiting
  2024-511442-39-00 5 2025-02-05 Rheumatoid arthritis (RA)
• DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMI … Recruiting
  2024-513475-41-00 5 2025-02-03 Multiple Sclerosis
• Intravenous Dexmedetomidine as an Adjuvant to Locoregional Anesthesia in Pediatric Surgery: A Prospective, Randomized, Double-Blind, Placebo … Recruiting
  2024-514550-73-00 4 2025-02-03 Loco-regional anesthesia in pediatric surgery
• Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting
  2023-509811-98-00 4 2025-01-07 Patients with HER2-positive locally advanced inoperable or metastatic
• Study of Artificial Intelligence-based Personalized Rituximab Treatment Protocol in Membranous nephropathy - iRITUX Recruiting
  2024-510718-34-00 11 2024-11-29 Membranous nephropathy
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• Multicentre randomised double-blind superiority trial with a roll-over phase to evaluate the efficacy of OM-89 vs placebo in reducing antibi … Recruiting
  2024-512595-35-00 5 2024-11-21 neurogenic bladder
• MK-1084 with Pembrolizumab in 1L Locally Advanced or Metastatic NSCLC With KRAS G12C Mutations and PD-L1 ≥50% Recruiting
  2023-507776-42-00 5 2024-11-14 Non-small cell lung cancer
• Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg … Recruiting
  2023-504620-26-00 4 2024-11-04 Triple negative breast cancer
• Reduction in the number of chemotherapy cycles in combination with Pembrolizumab in first-line treatment of PD-L1-positive recurrent or meta … Recruiting
  2024-514875-16-00 4 2024-10-21 First-line treatment of PD-L1-positive recurrent or metastatic head an
• An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch … Recruiting
  2024-516782-36-00 4 2024-10-15 metastatic or recurrent endometrial or ovarian carcinosarcoma
• Comparison between ABP 234 and Keytruda® (Pembrolizumab) Recruiting
  2024-514304-14-00 1 2024-10-08 Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
• ARGO Colchicine versus Placebo in Acute Myocarditis Patients to Reduce Late Gadolinium Enhancement Mass on Cardiac Magnetic Resonance and th … Recruiting
  2024-514610-13-00 5 2024-10-04 patients suffering from acute myocarditis confirmed on Cardiac magneti
• PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting
  2024-515297-27-00 5 2024-08-14 colon carcinoma
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro … Recruiting
  2023-508005-24-00 5 2024-08-01 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa … Recruiting
  2023-508260-30-01 5 2024-07-30 Patients with poor prognostic OVARian cancers based on the tumor prima
• Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu … Recruiting
  2024-515788-73-00 4 2024-07-30 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IM
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE) Recruiting
  2023-504251-27-00 7 2024-05-27 Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mut
• EstroTEP and circulating biomarkers for ER-positive HER2-negative metastatic breast cancer patients Recruiting
  2023-506282-66-00 5 2024-05-27 Women with ER+ HER2- metastatic breast cancer who progressed on first
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia Recruiting
  2022-502514-86-00 1 2024-02-07 Myeloproliferative Neoplasms
• A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting
  2022-502113-28-00 5 2024-02-01 Follicular lymphoma

Showing 97–120 of 249 trials